Oncolytic herpes simplex virus mutants are more efficacious than wild-type adenovirus type 5 for the treatment of high-risk neuroblastomas in preclinical models

Pediatric Blood and Cancer

Volumn 44, Issue 5, 2005, Pages 469-478

  Parikh, Nehal S ^a   Currier, Mark A ^a   Mahller, Yonatan Y ^a   Adams, Lisa C ^a   Di Pasquale, Betsy ^a   Collins, Margaret H ^a   Cripe, Timothy P ^a,b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b Division of Hematology/Oncology   (United States)

Author keywords

Adenovirus; As 24; Green fluorescent protein; Herpes simplex virus; Neuroblastoma; NV1066

Indexed keywords

COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; INTEGRIN RECEPTOR; ONCOLYTIC VIRUS; VIRUS PROTEIN;

ADENOVIRUS 5; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GRAFT; CANCER RISK; CONTROLLED STUDY; HERPES SIMPLEX VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MOUSE; NEUROBLASTOMA; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR MODEL; VIRUS ATTENUATION; VIRUS EXPRESSION; VIRUS MUTANT; VIRUS REPLICATION; WILD TYPE; XENOGRAFT;

ADENOVIRUSES, HUMAN; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; DISEASE SUSCEPTIBILITY; HUMANS; INTEGRINS; MICE; MICE, NUDE; MUTATION; NECROSIS; NEOPLASMS, EXPERIMENTAL; NEUROBLASTOMA; RECEPTORS, VIRUS; SIMPLEXVIRUS; TRANSPLANTATION, HETEROLOGOUS; VIRUS REPLICATION;

EID: 18144384382     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20268     Document Type: Article

References (69)

1. Shimada H, Umehara S, Monobe Y, et al. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: A report from the Children's Cancer Group. Cancer 2001;92:2451-2461.
2. Goto S, Umehara S, Gerbing RB, et al. Histopathology (International Neuroblasloma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: A report from the Children's Cancer Group. Cancer 2001;92:2699-2708.
3. Kuroda T, Saeki M, Honna T, et al. Clinical significance of intensive surgery with intraoperative radiation for advanced neuroblastoma: Does it really make sense? J Pediatr Surg 2003;38:1735-1738.
4. Matthay KK, Villablanca IG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-1173.
5. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111-1116.
6. Brodeur G, Marris IM. Neuroblastoma. In: Pizzo PA. Principles and practice of pediatric oncology. Philadelphia: Lippincott Williams & Wilkins; 2002. pp 895-938.
7. Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003;80:148-158.
8. Kirn D. Clinical research results with d11520 (Onyx-015): A replication-selective adenovirus for the treatment of cancer: What have we learned? Gene Ther 2001;8:89-98.
9. Ganly I, Kirn D, Eckhardt G, et al. A phase I study of Onyx-015: An E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 2000;6:798-806.
10. Nemunaitis J, Cunningham C, Buchanan A, et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: Safety, feasibility, and biological activity. Gene Ther 2001;8:746-759.
11. Reid T, Galanis E, Abbruzzese J, et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (d11520): Phase II viral, immunologic, and clinical endpoints. Cancer Res 2002;62:6070-6079.
12. Reid T, Warren R, Kirn D. Intravascular adenoviral agents in cancer patients: Lessons from clinical trials. Cancer Gene Ther 2002;9: 979-986.
13. Vasey PA, Shulman LN, Campos S, et al. Phase I trial of intraperitoneal injection of the E1B-55-kDa-gene-deleted adenovirus ONYX-015(d11520)givenondays 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol 2002;20:1562-1569.
14. Trudel S, Trachtenberg J, Toi A, et al. A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. Cancer Gene Ther 2003;10:755-763.
15. DeWeese TL, van der Poel H, Li S, et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 2001;61:7464-7472.
16. Cripe TP, Dunphy EJ, Holub AD, et al. Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. Cancer Res 2001; 61:2953-2960.
17. Dmitriev I, Krasnykh V, Miller CR, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998;72:9706-9713.
18. Douglas JT, Kim M, Sumerel LA, et al. Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors. Cancer Res 2001;61:813-817.
19. Hutchin ME, Pickles RJ, Yarbrough WG. Efficiency of adenovirus-mediated gene transfer to oropharyngeal epithelial cells correlates with cellular differentiation and human coxsackie and adenovirus receptor expression. Hum Gene Ther 2000;11:2365-2375.
20. Nemerow GR. Cell receptors involved in adenovirus entry. Virology 2000;274:1-4.
21. Pearson AS, Koch PE, Atkinson N, et al. Factors limiting adenovirus-mediated gene transfer into human lung and pancreatic cancer cell lines. Clin Cancer Res 1999;5:4208-4213.
22. Li D, Duan L, Freimuth P, et al. Variability of adenovirus receptor density influences gene transfer efficiency and therapeutic response in head and neck cancer. Clin Cancer Res 1999;5:4175-4181.
23. Li Y, Pong RC, Bergelson JM, et al. Loss of adenoviral receptor expression in human bladder cancer cells: A potential impact on the efficacy of gene therapy. Cancer Res 1999;59:325-330.
24. Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997;275:1320-1323.
25. Tomko RP, Xu R, Philipson L. HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 1997;94:3352-3356.
26. Wickham TJ, Mathias P, Cheresh DA, et al. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993;73:309-319.
27. Wickham TJ, Filardo EJ, Cheresh DA, et al. Integrin alpha v beta 5 selectively promotes adenovirus mediated cell membrane permeabilization. J Cell Biol 1994;127:257-264.
28. Nemerow GR, Stewart PL. Role of alpha(v) integrins in adenovirus cell entry and gene delivery. Microbiol Mol Biol Rev 1999;63: 725-734.
29. Goldman MJ, Wilson JM. Expression of alpha v beta 5 integrin is necessary for efficient adenovirus-mediated gene transfer in the human airway. J Virol 1995;69:5951-5958.
30. Croyle MA, Walter E, Janich S, et al. Role of integrin expression in adenovirus-mediated gene delivery to the intestinal epithelium. Hum Gene Ther 1998;9:561-573.
31. Bruning A, Kohler T, Quist S, et al. Adenoviral transduction efficiency of ovarian cancer cells can be limited by loss of integrin beta3 subunit expression and increased by reconstitution of integrin alphavbeta3. Hum Gene Ther 2001;12:391-399.
32. Davison E, Kirby I, Whitehouse J, et al. Adenovirus type 5 uptake by lung adenocarcinoma cells in culture correlates with Ad5 fibre binding is mediated by alpha(v)beta1 integrin and can be modulated by changes in beta1 integrin function. J Gene Med 2001;3:550-559.
33. Khan J, Wei JS, Ringner M, et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 2001;7:673-679.
34. Davidoff AM, Kimbrough SA, Ng CY, et al. Neuroblastoma regression and immunity induced by transgenic expression of interleukin-12. J Pediatr Surg 1999;34:902-906; discussion 906-907.
35. Davidoff AM, Stevenson SC, McClelland A, et al. Enhanced neuroblastoma transduction for an improved antitumor vaccine. J Surg Res 1999;83:95-99.
36. Joseph JM, Bouquet C, Opolon P, et al. High level of stabilized angiostatin mediated by adenovirus delivery does not impair the growth of human neuroblastoma xenografts. Cancer Gene Ther 2003;10:859-866.
37. Adachi Y, Reynolds PN, Yamamoto M, et al. Midkine promoter-based adenoviral vector gene delivery for pediatric solid tumors. Cancer Res 2000;60:4305-4310.
38. Adachi Y, Reynolds PN, Yamamoto M, et al. A midkine promoter-based conditionally replicative adenovirus for treatment of pediatric solid tumors and bone marrow tumor purging. Cancer Res 2001;61:7882-7888.
39. Meek MM, Wierdl M, Wagner LM, et al. A virus-directed enzyme prodrug therapy approach to purging neuroblastoma cells from hematopoietic cells using adenovirus encoding rabbit carboxylesterase and CPT-11. Cancer Res 2001;61:5083-5089.
40. Wagner LM, Guichard SM, Burger RA, et al. Efficacy and toxicity of a virus-directed enzyme prodrug therapy purging method: Preclinical assessment and application to bone marrow samples from neuroblastoma patients. Cancer Res 2002;62:5001-5007.
41. Roizman BS. A. Herpes simplex viruses and their replication. In: Fields DMKBN. Fields virology. 3rd edition. Philadelphia: Lippincott-Raven Publishers; 1996. pp 2231-2295.
42. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial. Gene Ther 2000;7: 867-874.
43. Rampling R, Cruickshank G, Papanastassiou V, et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 2000;7:859-866.
44. Oyama M, Ohigashi T, Hoshi M, et al. Intravesical and intravenous therapy of human bladder cancer by the herpes vector G207. Hum Gene Ther 2000;11:1683-1693.
45. Coukos G, Makrigiannakis A, Montas S, et al. Multi-attenuated herpes simplex virus-I mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy. Cancer Gene Ther 2000;7:275-283.
46. Walker JR, McGeagh KG, Sundaresan P, et al. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum Gene Ther 1999;10:2237-2243.
47. Kasuya H, Nishiyama Y, Nomoto S, et al. Intraperitoneal delivery of hrR3 and ganciclovir prolongs survival in mice with disseminated pancreatic cancer. J Surg Oncol 1999;72:136-141.
48. Carew JF, Kooby DA, Halterman MW, et al. Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207). Hum Gene Ther 1999;10:1599-1606.
49. Toda M, Rabkin SD, Martuza RL. Treatment of human breast cancer in a brain metastatic model by G207: A replication-competent multimutated herpes simplex virus 1. Hum Gene Ther 1998;9:2177-2185.
50. Pawlik TM, Nakamura H, Yoon SS, et al. Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus. Cancer Res 2000;60:2790-2795.
51. Stiles BM, Bhargava A, Adusumilli PS, et al. The replication-competent oncolytic herpes simplex mutant virus NV1066 is effective in the treatment of esophageal cancer. Surgery 2003;134: 357-364.
52. Stanziale SF, Stiles BM, Bhargava A, et al. Oncolytic herpes simplex virus-1 mutant expressing green fluorescent protein can detect and treat peritoneal cancer. Hum Gene Ther 2004;15:609-618.
53. Stiles BM, Bhargava A, Adusumilli PS, et al. The replication-competent oncolytic herpes simplex mutant virus NV1066 is effective in the treatment of esophageal cancer. Surgery 2003;134: 357-364.
54. MacKie RM, Stewart B, Brown SM. Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet 2001;357:525-526.
55. Ross RA, Spengler BA, Biedler JL. Coordinate morphological and biochemical interconversion of human neuroblastoma cells. J Natl Cancer Inst 1983;71:741-747.
56. Keshelava N, Seeger RC, Groshen S, et al. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 1998;58:5396-5405.
57. Giard DJ, Aaronson SA, Todaro GJ, et al. In vitro cultivation of human tumors: Establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 1973;51:1417-1423.
58. Huang S, Kamata T, Takada Y, et al. Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cells. J Virol 1996;70:4502-4508.
59. Lieber M, Smith B, Szakal A, et al. A continuous tumor-cell line from a human lung carcinoma with properties of type II alveolar epithelial cells. Int J Cancer 1976;17:62-70.
60. Suzuki K, Alemany R, Yamamoto M, et al. The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. Clin Cancer Res 2002;8:3348-3359.
61. Meignier B, Longnecker R, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: Construction and evaluation in rodents. J Infect Dis 1988;158: 602-614.
62. Mineta T, Rabkin SD, Yazaki T, et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995;1:938-943.
63. Wei M, Tamiya T, Chase M, et al. Experimental tumor therapy in mice with the cyclophos-phamide-activating cytochrome P450 2B1 gene. Hum Gene Ther 1994;5:969-978.
64. Cripe TP, Holub A, Saini A, et al. Lack of the adenovirus major attachment receptor limits oncolysis of human rhabdomyosarcoma cells by adenovirus. Proc Am Assoc Can Res 2000;41:452.
65. Bharatan N, Currier M, Cripe T. Differential susceptibility of pediatric sarcoma cells to oncolysis by conditionally replication-competent herpes simplex viruses. J Pediatr Hem Oncol 2001;24: 447-453.
66. La Quaglia MP, Kushner BH, Su W, et al. The impact of gross total resection on local control and survival in high-risk neuroblastoma. J Pediatr Surg 2004;39:412-417.
67. Wong RJ, Chan MK, Yu Z, et al. Effective intravenous therapy of murine pulmonary metastases with an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res 2004;10:251-259.
68. Schmidt ML, Lal A, Seeger R, et al. Favorable prognosis for patients ages 12-18 months with stage 4 MYCN-nonamplified neuroblastoma. Proc Am Soc Clin Oncol 2003;22:800.
69. Fong Y, Kemeny N, Jarnagin W, et al. Phase 1 study of a replication-competent herpes simplex oncolytic virus for treatment of hepatic colorectal metastases. Proc Am Soc Clin Oncol 2002;21:8A.